Navigation Links
Younger Adults Increasingly Treated for Heart Disease-related Conditions
Date:10/30/2007

could be the result of the growing obesity epidemic and various lifestyle factors."

Not only were the increases among 20-44 year olds significant, but so too were the rates of increase when compared to age groups more traditionally associated with these categories of medications. The increase in the number of 20-44 year-olds on lipid-lowering medications was 37 percent higher than it was for 45 to 64 year olds; the growth in prevalence of those on antihypertensives was 52 percent greater. When compared with patients 65 years or older, the increase in usage of lipid-lowering medications was 31 percent higher in the 20-44 group, and among those on antihypertensives it was more than double.

Decline Seen in Age of Patients on Drug Treatment

The analysis also found a significant shift downward in the age of patients using these drug treatments. In 2006, half of all patients on lipid- lowering drugs were 61 years old or younger; the median age of women fell more sharply than men, dropping from 67 to 62 in the six-year span, as compared to 62 to 59 for men.

The median age of those using antihypertensives declined four years over the six-year period, with half of all patients on these drugs being 60 years or younger in 2006; again women had the greatest decline, dropping from 65 to 60 versus men whose median age fell from 63 to 60.

"There is a history of women being under-diagnosed and under-treated for heart conditions," said Epstein. "The fact that more women at a younger age are receiving medication treatment for high cholesterol and hypertension is a sign that the medical community is recognizing that heart disease is a serious threat to women as well as men."

Heart Disease Risks

High cholesterol and high blood pressure are two of the leading risk factors for heart disease, heart attack and stroke. High LDL cholesterol can cause atherosclerosis, a narrowing and hardening of the arteries that feed the heart and brain. High blood
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
3. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
4. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
5. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
6. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
7. FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications
8. New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
9. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
10. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...e-FirstCall/ -- GeoVax Labs, Inc.,(OTC Bulletin B...y developing,human vaccines for diseases caused b...infectious agents, announced today that the launch...lace in twelve sites across North and South Americ...th The National Institutes of,Health (NIH), and t...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/25/2008)...ove recovery , , Audio and Web Video Resour...ayo Clinic News Blog. Please see the bottom of thi...Minn., Nov. 25 A Mayo C...n,t think they,re having a stroke -- and as a resu...n worsens. The findings appear in the current issu...
(Date:11/25/2008)... Pharmacyclics, Inc.,(N...as completed a Phase 1,clinical trial with PCI-27...lecule Factor VIIa inhibitor. The trial was conduc...e the safety and pharmacologic effect of,PCI-2748...n a linear dose,response in the International Nor...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Research Attributes Lack of HIV AIDS Vaccine to Use of Chimpanzees 3225 1Research Attributes Lack of HIV AIDS Vaccine to Use of Chimpanzees 3225 2Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 5246 1Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 5246 2Surface tension drives segregation within cell mixtures 5244 1Surface tension drives segregation within cell mixtures 5244 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 1Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 3
...ase 1 Colorectal and Prostate Cancer,Trials To Be ...RANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCa...ceutical company,focused on oncology, today announ...the Company,s lead product candidate, in patients,...ed in a poster,session at the 43rd Annual Meeting ...
...07 /PRNewswire-FirstCall/ -- Vical,Incorporated to...study, a DNA vaccine formulated with the company,s...needle-free injection,yielded significantly higher...ne delivered by needle and syringe. In a,separate ...of,unformulated vaccine yielded comparable improve...
Other Medicine Technology:Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 2Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 3Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 4Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 2Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 3Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 4
(Date:12/2/2008)...a leading provider of onsite health services and t...e, the athletic products company, has selected Mar...te health clinics and to provide health services t... Burlington, VT (PRWEB) Decem... of onsite employee health services and technology...
(Date:12/2/2008)...nal Day of Disabled Persons is recognized on Dec. ...g boy born with backwards pointing feet. After fre...ospital docked in Liberia, Benedict,s feet are cor...children his age. High resolution photos and vid...g , Garden Valley, TX (V...
(Date:12/2/2008)...unces that the SouthEast Alaska Regional Health Co...the Rhapsody™ Integration Engine to help the...armacy, laboratory and business programs communica...tivity to statewide systems such as VacTrAK (the S...an MIS and clinical documentation tool used by sub...
(Date:12/2/2008)...orola, Inc. (NYSE: MOT ),announced today that i...enable,three hospitals managed by leading Europea...to deliver voice, data and video services. The inn... broadband infrastructure to support,multimedia s..., eliminating,the need for additional cabling or ...
Breaking Medicine News(10 mins):Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Mercy Ships Recognizes International Day of Disabled Persons 2Health News:Mercy Ships Recognizes International Day of Disabled Persons 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 2Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 3
...al cardiologist at the Washington Hospital Center ...ergy) to restore blood flow in blocked arteries. /...eople suffering from advanced diabetes as it leads...ns such as amputation. People with diabetes and e...
...s of Kryptiq's Care Manager Diabetes Module at the...ems Society (HIMSS) conference. // This module ...nts who benefited. The one year study showed that ...holesterol and blood pressure levels. Providence M...
...y men contact in Hong Kong has been in a way respo... a latest report. // Government health officials ...vember 2005, had HIV with similar gene sequencing,...st reported. The discovery was made when all the ...
...d be as simple as swallowing a spongy pill with a ...ts of Cambridge University researchers // that can... UK every year. It is the ninth most commonly occu...he windpipe, the pill is pulled out, gently scrapi...
Other Medicine News:Health News:Laser Used To Clear Blocked Arteries Preventing Amputation, 2Health News:Kryptiq Care Manager Diabetes Module Effective In Managing Diabetes 2
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 5-8; contains 1 bottle each of 20 nm and 40 nm Naked Gold
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 12 OD
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 50 OD
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 12 OD
Medicine Products: